IOA-289

DRUG2 trials

Sponsors

iOnctura

Conditions

HealthyMetastatic Pancreatic Cancer

Phase 1

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

CompletedNCT05027568

iOncturaHealthy

Start: 2021-06-28End: 2021-09-07Updated: 2025-03-20

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

CompletedNCT05586516

iOncturaMetastatic Pancreatic Cancer

Start: 2022-10-10End: 2025-08-18Updated: 2026-03-30

Related Papers

Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2024-06-014 citations